Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB. Schiff MH, et al. Among authors: mueller rb. Ann Rheum Dis. 2014 Dec;73(12):2174-7. doi: 10.1136/annrheumdis-2014-205325. Epub 2014 Jun 27. Ann Rheum Dis. 2014. PMID: 24972708 Clinical Trial.
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B, Toniolo M, Exer P, Gabay C, Finckh A; physicians of the Swiss Clinical Quality Management Cohort. Nissen MJ, et al. Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691. Arthritis Rheumatol. 2016. PMID: 27015429 Free article.
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
Mueller RB, Reshiti N, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, Schiff M, Spaeth M, von Kempis J; SCQM physicians. Mueller RB, et al. Clin Rheumatol. 2017 Jan;36(1):59-66. doi: 10.1007/s10067-016-3468-6. Epub 2016 Nov 12. Clin Rheumatol. 2017. PMID: 27838788 Free article.
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis.
Alpizar-Rodriguez D, Brulhart L, Mueller RB, Möller B, Dudler J, Ciurea A, Walker UA, Von Mühlenen I, Kyburz D, Zufferey P, Mahler M, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen MJ, Courvoisier DS, Gabay C, Finckh A. Alpizar-Rodriguez D, et al. Among authors: mueller rb. Clin Rheumatol. 2017 Mar;36(3):677-682. doi: 10.1007/s10067-017-3547-3. Epub 2017 Jan 21. Clin Rheumatol. 2017. PMID: 28110385 Free article.
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study.
Mueller RB, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Mueller RB, et al. Clin Rheumatol. 2017 Oct;36(10):2187-2192. doi: 10.1007/s10067-017-3779-2. Epub 2017 Aug 3. Clin Rheumatol. 2017. PMID: 28776300 Clinical Trial.
44 results